Market Research Life Sciences Market Research Pharmaceuticals Market Research Manufacturing, Packaging & Detailing Market Research

Active Pharmaceutical Ingredients CDMO Market (API-CDMO) by Drug (Generics, Innovative), Product (Antibody Drug Conjugate, Highly Potent Active Pharmaceutical Ingredient, Traditional Active Pharmaceutical Ingredient), Synthesis, Workflow, Application - Gl

Best Price Guarantee Length Publisher Published Date SKU
from $4,749 198 Pages 360iResearch January, 2024 IRE18417884
Best Price Guarantee
Price from $4,749
Length 198 Pages
Publisher 360iResearch
Published Date January, 2024
SKU IRE18417884

Active Pharmaceutical Ingredients CDMO Market (API-CDMO) by Drug (Generics, Innovative), Product (Antibody Drug Conjugate, Highly Potent Active Pharmaceutical Ingredient, Traditional Active Pharmaceutical Ingredient), Synthesis, Workflow, Application - Global Forecast 2024-2030


The Active Pharmaceutical Ingredients CDMO Market size was estimated at USD 114.85 billion in 2023 and expected to reach USD 126.42 billion in 2024, at a CAGR 10.38% to reach USD 229.39 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Active Pharmaceutical Ingredients CDMO Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Active Pharmaceutical Ingredients CDMO Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Active Pharmaceutical Ingredients CDMO Market, highlighting leading vendors and their innovative profiles. These include 5N Plus, A. R. Life Sciences Pvt. Ltd., AbbVie Inc., abcr GmbH, Biocon Limited, Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Corden Pharma International GmbH, Curia Global, Inc., Dr. Reddy’s Laboratories Ltd., Evonik Industries AG, IOL Chemicals and Pharmaceuticals Limited, Jungbunzlauer Suisse AG, Lonza Group Ltd., Lupin Limited, Minafin Group, Mylan Inc., Olon S.p.A., Piramal Group, PMC Group, Inc., Polpharma SA, Recipharm AB, Samsung Biologics, SEQENS, Siegfried AG, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Tiefenbacher API + Ingredients GmbH & Co. KG, and Xellia Pharmaceuticals ApS by Novo Holdings A/S.

Market Segmentation & Coverage

This research report categorizes the Active Pharmaceutical Ingredients CDMO Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug

Generics
  • Innovative
  • Product

    Antibody Drug Conjugate
  • Highly Potent Active Pharmaceutical Ingredient
  • Traditional Active Pharmaceutical Ingredient
  • Synthesis

    Biotech
  • Synthetic
  • Workflow

    Clinical
  • Commercial
  • Application

    Cardiovascular
  • Diabetes
  • Glaucoma
  • Hormonal
  • Oncology
  • Region

    Americas

    Argentina
  • Brazil
  • Canada
  • Mexico
  • United States

    California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas
  • Asia-Pacific

    Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam
  • Europe, Middle East & Africa

    Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom
    The report offers valuable insights on the following aspects:

    1. Market Penetration: It presents comprehensive information on the market provided by key players.
    2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
    3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
    4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
    5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
    The report addresses key questions such as:

    1. What is the market size and forecast of the Active Pharmaceutical Ingredients CDMO Market?
    2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Active Pharmaceutical Ingredients CDMO Market?
    3. What are the technology trends and regulatory frameworks in the Active Pharmaceutical Ingredients CDMO Market?
    4. What is the market share of the leading vendors in the Active Pharmaceutical Ingredients CDMO Market?
    5. Which modes and strategic moves are suitable for entering the Active Pharmaceutical Ingredients CDMO Market?


    Note: PDF & Excel + Online Access - 1 Year


    • 1. Preface
    1.1. Objectives of the Study
    1.2. Market Segmentation & Coverage
    1.3. Years Considered for the Study
    1.4. Currency & Pricing
    1.5. Language
    1.6. Limitations
    1.7. Assumptions
    1.8. Stakeholders
    2. Research Methodology
    2.1. Define: Research Objective
    2.2. Determine: Research Design
    2.3. Prepare: Research Instrument
    2.4. Collect: Data Source
    2.5. Analyze: Data Interpretation
    2.6. Formulate: Data Verification
    2.7. Publish: Research Report
    2.8. Repeat: Report Update
    3. Executive Summary
    4. Market Overview
    4.1. Introduction
    4.2. Active Pharmaceutical Ingredients CDMO Market, by Region
    5. Market Insights
    5.1. Market Dynamics
    5.1.1. Drivers
    5.1.1.1. Rising demand for generic drugs and increasing consumption of biopharmaceuticals
    5.1.1.2. Growth of small molecules, rising active pharmaceutical ingredient (API) complexity
    5.1.1.3. Growing demand for targeted cancer and other medical treatments
    5.1.2. Restraints
    5.1.2.1. Issues associated with compliances while outsourcing
    5.1.3. Opportunities
    5.1.3.1. Increasing R&D investment for active pharmaceutical ingredients CDMO
    5.1.3.2. Proliferating sophistication in oncology drug research
    5.1.4. Challenges
    5.1.4.1. Stringent regulatory compliance requirements for API CDMO
    5.2. Market Segmentation Analysis
    5.3. Market Trend Analysis
    5.4. Cumulative Impact of High Inflation
    5.5. Porter’s Five Forces Analysis
    5.5.1. Threat of New Entrants
    5.5.2. Threat of Substitutes
    5.5.3. Bargaining Power of Customers
    5.5.4. Bargaining Power of Suppliers
    5.5.5. Industry Rivalry
    5.6. Value Chain & Critical Path Analysis
    5.7. Regulatory Framework
    6. Active Pharmaceutical Ingredients CDMO Market, by Drug
    6.1. Introduction
    6.2. Generics
    6.3. Innovative
    7. Active Pharmaceutical Ingredients CDMO Market, by Product
    7.1. Introduction
    7.2. Antibody Drug Conjugate
    7.3. Highly Potent Active Pharmaceutical Ingredient
    7.4. Traditional Active Pharmaceutical Ingredient
    8. Active Pharmaceutical Ingredients CDMO Market, by Synthesis
    8.1. Introduction
    8.2. Biotech
    8.3. Synthetic
    9. Active Pharmaceutical Ingredients CDMO Market, by Workflow
    9.1. Introduction
    9.2. Clinical
    9.3. Commercial
    10. Active Pharmaceutical Ingredients CDMO Market, by Application
    10.1. Introduction
    10.2. Cardiovascular
    10.3. Diabetes
    10.4. Glaucoma
    10.5. Hormonal
    10.6. Oncology
    11. Americas Active Pharmaceutical Ingredients CDMO Market
    11.1. Introduction
    11.2. Argentina
    11.3. Brazil
    11.4. Canada
    11.5. Mexico
    11.6. United States
    12. Asia-Pacific Active Pharmaceutical Ingredients CDMO Market
    12.1. Introduction
    12.2. Australia
    12.3. China
    12.4. India
    12.5. Indonesia
    12.6. Japan
    12.7. Malaysia
    12.8. Philippines
    12.9. Singapore
    12.10. South Korea
    12.11. Taiwan
    12.12. Thailand
    12.13. Vietnam
    13. Europe, Middle East & Africa Active Pharmaceutical Ingredients CDMO Market
    13.1. Introduction
    13.2. Denmark
    13.3. Egypt
    13.4. Finland
    13.5. France
    13.6. Germany
    13.7. Israel
    13.8. Italy
    13.9. Netherlands
    13.10. Nigeria
    13.11. Norway
    13.12. Poland
    13.13. Qatar
    13.14. Russia
    13.15. Saudi Arabia
    13.16. South Africa
    13.17. Spain
    13.18. Sweden
    13.19. Switzerland
    13.20. Turkey
    13.21. United Arab Emirates
    13.22. United Kingdom
    14. Competitive Landscape
    14.1. FPNV Positioning Matrix
    14.2. Market Share Analysis, By Key Player
    14.3. Competitive Scenario Analysis, By Key Player
    15. Competitive Portfolio
    15.1. Key Company Profiles
    15.1.1. 5N Plus
    15.1.2. A. R. Life Sciences Pvt. Ltd.
    15.1.3. AbbVie Inc.
    15.1.4. abcr GmbH
    15.1.5. Biocon Limited
    15.1.6. Boehringer Ingelheim International GmbH
    15.1.7. Cambrex Corporation
    15.1.8. Catalent, Inc.
    15.1.9. Corden Pharma International GmbH
    15.1.10. Curia Global, Inc.
    15.1.11. Dr. Reddy’s Laboratories Ltd.
    15.1.12. Evonik Industries AG
    15.1.13. IOL Chemicals and Pharmaceuticals Limited
    15.1.14. Jungbunzlauer Suisse AG
    15.1.15. Lonza Group Ltd.
    15.1.16. Lupin Limited
    15.1.17. Minafin Group
    15.1.18. Mylan Inc.
    15.1.19. Olon S.p.A.
    15.1.20. Piramal Group
    15.1.21. PMC Group, Inc.
    15.1.22. Polpharma SA
    15.1.23. Recipharm AB
    15.1.24. Samsung Biologics
    15.1.25. SEQENS
    15.1.26. Siegfried AG
    15.1.27. Sun Pharmaceutical Industries Limited
    15.1.28. Teva Pharmaceutical Industries Ltd.
    15.1.29. Tiefenbacher API + Ingredients GmbH & Co. KG
    15.1.30. Xellia Pharmaceuticals ApS by Novo Holdings A/S
    15.2. Key Product Portfolio
    16. Appendix
    16.1. Discussion Guide
    16.2. License & Pricing
    FIGURE 1. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET RESEARCH PROCESS
    FIGURE 2. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2023 VS 2030
    FIGURE 3. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
    FIGURE 4. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY REGION, 2023 VS 2030 (%)
    FIGURE 5. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 6. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET DYNAMICS
    FIGURE 7. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
    FIGURE 8. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 9. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
    FIGURE 10. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 11. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2023 VS 2030 (%)
    FIGURE 12. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 13. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2023 VS 2030 (%)
    FIGURE 14. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 15. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
    FIGURE 16. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 17. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 18. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 19. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
    FIGURE 20. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 21. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 22. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 25. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET, FPNV POSITIONING MATRIX, 2023
    FIGURE 26. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SHARE, BY KEY PLAYER, 2023

    $4,749
    $5,749
    $6,749
    $8,749

    Research Assistance

    US: 800.298.5699
    Int'l: +1.240.747.3093
    Live help
    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Other tasks

    Cookie Settings